Document is current

Article History

Received: 17 March 2023

Accepted: 10 May 2023

First Online: 16 May 2023

Declarations

:

: Participants and study partners were recruited, and this study was conducted in accordance with Good Clinical Practice guidelines and approved by the Institutional Review Board (IRB #2016–0351) at GUMC as well as GHUCCTS scientific review board. The study was conducted under FDA Investigational New Drug (IND) #130732 and registered in ClinicalTrials.gov (NCT02947893. All samples collected and used for experiments presented in this study were de-identified and relabeled with a study ID.

: Consent for publication was obtained as part of patient’s informed consent.

: C.M. is an inventor on several US and international Georgetown University patents to use nilotinib and other tyrosine kinase inhibitors as a treatment for neurodegenerative diseases. Georgetown University and C.M are shareholders in KeifeRX LLC, a biopharmaceutical company, from which C.M. receives consulting fees and is a co-founder. C.M. receives consulting fees from SkyBio LLC and research grants from NIH–NIA and Sun Pharmaceuticals Advanced Research Corporation (SPARC). RST reports research support to Georgetown University from Alector, Biogen, Eisai, Janssen, Lilly, Roche/Genentech, Vaccinex, and Vivoryon. The remaining authors have no potential competing interests.